Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.18 USD

41.18
3,160,813

+0.86 (2.13%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $41.19 +0.01 (0.02%) 5:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates

by Zacks Equity Research

Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.

Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.

Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Bayer's (BAYRY) fourth-quarter 2018 core earnings per share of 31 cents, per American Depositary Receipt ("ADR"), beat the Zacks Consensus Estimate of 26 cents.

Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2018.

Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover

by Zacks Equity Research

Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.

AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

by Zacks Equity Research

AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.

Top Ranked Income Stocks to Buy for February 27th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 27th:

Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron (REGN) disagree with a jury verdict in favor of Amgen upholding the validity of two patents related to Repatha.

The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto

Top Ranked Income Stocks to Buy for February 26th

by Zacks Equity Research

Here are three stocks with buy rank and strong income characteristics for investors to consider today, February 26th:

John Blank headshot

Kick the Can Entertains the Anglo Masses: Global Week Ahead

by John Blank

"Metaphorically, the phrase means??to defer conclusive action with a short-term solution."

Novartis In-Licenses Rights to Heart Candidate From Ionis

by Zacks Equity Research

Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.

Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates

by Zacks Equity Research

Emergent (EBS) rides high on both earnings and a revenue beat in Q4.

Top Ranked Income Stocks to Buy for February 22nd

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 22nd

Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Sweta Killa

Sector ETF report for PPH

Merck Gets Priority Review for Keytruda in Third-Line SCLC

by Zacks Equity Research

Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.

Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct

by Zacks Equity Research

Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.

Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

by Zacks Equity Research

Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

Nitish Marwah headshot

New Strong Buy Stocks for February 19th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Top Ranked Growth Stocks to Buy for February 15th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 15th

Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

by Zacks Equity Research

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up

by Zacks Equity Research

Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.

AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 14th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday